In one paragraphArticle in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
20 authors.
Amal T ElhawUPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.ORCID 0000-0001-6547-3018 Priscilla W TangUPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.ORCID 0000-0002-6081-4001 Ya-Yun ChengUPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.ORCID 0000-0002-2472-0577 Shriya KamlapurkarUPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.ORCID 0000-0002-2686-3387 Zaineb JavedUPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.ORCID 0000-0003-1336-2564 Sarah Al-SaadUPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.ORCID 0009-0005-4125-5047 Sierra R WhiteUPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.ORCID 0000-0003-0764-9585 Ahmed Emam AbdelnabyDepartment of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.ORCID 0000-0003-4775-3643 Hannah KhanUPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Alex Seok ChoiDepartment of Pathology and O'Neal Comprehensive Cancer Center, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.ORCID 0000-0002-5410-6906 Aidan R ColeUPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.ORCID 0000-0001-9647-0848 Yeon-Soo KimDepartment of Pharmacology, College of Medicine, Pennsylvania State University, Hershey, PA, USA.
Huda I AtiyaUPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Mohamed TrebakUPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.ORCID 0000-0001-6759-864X Ioannis ZervantonakisUPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.ORCID 0000-0003-2386-9553 Ronald J BuckanovichUPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.ORCID 0000-0002-5665-9790 Katherine M AirdUPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.ORCID 0000-0002-5828-2325 Lan G CoffmanUPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.ORCID 0000-0002-3753-1652 Karthikeyan MythreyeDepartment of Pathology and O'Neal Comprehensive Cancer Center, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.ORCID 0000-0001-5478-0098 Nadine HempelUPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.ORCID 0000-0002-5574-8783 Funding
VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Jessie Nedrow · 1988 to 2026
$158.0MProject 3: Hedgehog Inhibition to Enhance Response to ICI TherapyP50CA272218 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Ronald J Buckanovich, Robert Page Edwards · 2023 to 2026
$11.0MCa2+ Signaling Networks in Health and DiseaseR35HL150778 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI TREBAK, MOHAMED · 2020 to 2025
$5.4MTranslational Pulmonary Vascular BiologyT32HL110849 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Sruti Shiva · 2012 to 2026
$5.0MRole of Sox2 in Stress Adaptations to Ovarian Cancer Anchorage IndependenceR01CA230628 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI HEMPEL, NADINE, KARTHIKEYAN, MYTHREYE · 2019 to 2023
$2.1MRegulation of mitochondrial redox homeostasis and signaling in metastatic ovarian cancerR01CA242021 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI HEMPEL, NADINE · 2020 to 2024
$1.8MNCI NIH HHS P30 CA047904NCI NIH HHS P50 CA272218NCI NIH HHS R01 CA230628NCI NIH HHS R01 CA242021NHLBI NIH HHS R35 HL150778NHLBI NIH HHS T32 HL110849
6 · The paper itselfAbstract
All ovarian cancer subtypes spread via transcoelomic metastasis, where cells disseminate into the peritoneal fluid, resist anoikis, and form multicellular aggregates that invade the peritoneum. This represents the main driver of morbidity and mortality for peritoneal cancer patients. Mechanisms necessary for cancer cells to survive matrix detachment and initiate transcoelomic metastasis remain poorly defined. To address this, we identified a conserved detachment-sensitive gene signature activated shortly after matrix-detachment across multiple ascites-derived cancer cell lines. RHOV, an atypical, constitutively active and understudied member of the Rho GTPase family, emerged as a top upregulated transcript, which was confirmed in patient ascites-derived tumor cells. Functionally, loss of RHOV impairs anoikis resistance, multicellular aggregate integrity, migration and invasion, and completely abolishes transcoelomic tumor progression
Identifiers
PMID40832333
PMCPMC12363840
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390